SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Aug 20, 2018

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Aug. 20, 2018 · CIK: 0000894158 · Accession: 0001144204-18-045633

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-226500

Date

August 20, 2018

Author

Steven A. Shallcross

Form

CORRESP

Company

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)

Letter

VIA EDGAR United States Securities Division of Corporation Finance Office of Healthcare & Insurance Attention: Ms. Irene Paik Re: Synthetic Biologics, Inc. Registration Statement on Form S-3 Filed August 1, 2018 File No. 333-226500

Dear Mss. Paik and Westbrook:

Synthetic Biologics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 so that it may become effective at 5:00 p.m. (New York City Time) on Wednesday, August 22, 2018, or as soon thereafter as reasonably practicable.

The Company hereby authorizes its legal counsel, Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Very truly yours,
SYNTHETIC BIOLOGICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

    August 20, 2018

VIA EDGAR

United States Securities

and Exchange Commission

Division of Corporation Finance

Office of Healthcare & Insurance

100 F Street, NE

Washington, D.C. 20549

 Attention: Ms. Irene Paik

Ms.
Christine Westbrook

 Re: Synthetic Biologics, Inc.

Registration
Statement on Form S-3

Filed
August 1, 2018

File
No. 333-226500

Dear Mss. Paik and Westbrook:

Synthetic Biologics,
Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement
on Form S-3 so that it may become effective at 5:00 p.m. (New York City Time) on Wednesday, August 22, 2018,
or as soon thereafter as reasonably practicable.

The Company hereby
authorizes its legal counsel, Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP, to orally modify or withdraw this
request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with
any questions you may have concerning this request, and please notify either of them when this request for acceleration has been
granted.

    Very truly yours,

    SYNTHETIC BIOLOGICS, INC.

    By:
    /s/ Steven A. Shallcross

    Name:
Title:
    Steven A. Shallcross
Interim Chief Executive
Officer and Chief Financial Officer

SecProbe.io